Ligand Pharmaceuticals LGND Tolerance Therapeutics (Tzield®) — Financial Royalty Assets, Allowance

Other product segments

Qarziba

$480K—

Similar metrics at other companies

IONSTax Credit Carryforward Valuation Allowance

$1.24B+9.5%

TEXValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

-$1M+55.6%

WELLValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

$27.54M+55.9%

KEYSDeferred Tax Assets, Valuation Allowance

$497M+128%

CARRDeferred Tax Assets, Valuation Allowance

$1.54B+6.7%

ONDSValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

$4.59M+114%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — financial royalty assets, allowance.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported tolerance therapeutics (tzield®) — financial royalty assets, allowance of $97K in Q1 2026.
What does tolerance therapeutics (tzield®) — financial royalty assets, allowance mean?: This metric represents the cumulative valuation adjustments, such as allowances for credit losses or impairment charges, applied to the gross carrying value of the Tzield royalty asset. It reflects management's assessment of potential risks or collectability issues regarding future royalty payments. A significant increase in this allowance may signal deteriorating expectations for the underlying product's commercial performance.